Quick Answer
Cardiff Oncology, Inc. reported Revenue (ASC 606) of $593.0 thousand for fiscal year 2025.
Cardiff Oncology, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $593.0K | -13.2% |
| 2024 | $683.0K | +40.0% |
| 2023 | $488.0K | +26.4% |
| 2022 | $386.0K | +7.5% |
| 2021 | $359.0K | -1.9% |
| 2020 | $366.0K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $120.0K | -27.3% | -0.8% |
| June 30, 2025 | $121.0K | -25.8% | +11.0% |
| March 31, 2025 | $109.0K | -46.8% | -33.9% |
| September 30, 2024 | $165.0K | +17.0% | +1.2% |
| June 30, 2024 | $163.0K | +50.9% | -20.5% |
| March 31, 2024 | $205.0K | +147.0% | +45.4% |
| September 30, 2023 | $141.0K | +51.6% | +30.6% |
| June 30, 2023 | $108.0K | +18.7% | +30.1% |
- Cardiff Oncology, Inc. showed a decrease of -13.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2020–2025 period, Cardiff Oncology, Inc.’s revenue (asc 606) has grown by 62.0% (from $366.0 thousand to $593.0 thousand).
- The most recent figure is from Cardiff Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: